Biomarkers of Tumour Radiosensitivity and Predicting Benefit from Radiotherapy.

[1]  R. Huddart,et al.  LIFE AND DEATH OF SPARE (SELECTIVE BLADDER PRESERVATION AGAINST RADICAL EXCISION): REFLECTIONS ON WHY THE SPARE TRIAL CLOSED , 2010, BJU international.

[2]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[3]  Yudi Pawitan,et al.  Validation of a Radiosensitivity Molecular Signature in Breast Cancer , 2012, Clinical Cancer Research.

[4]  Daniel J Sargent,et al.  Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Arndt Hartmann,et al.  Expression of TIP60 (tat‐interactive protein) and MRE11 (meiotic recombination 11 homolog) predict treatment‐specific outcome of localised invasive bladder cancer , 2012, BJU international.

[6]  A. Horwich,et al.  Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  Michael C. Joiner,et al.  Basic Clinical Radiobiology , 2009 .

[8]  Ananya Choudhury,et al.  MRE11 expression is predictive of cause-specific survival following radical radiotherapy for muscle-invasive bladder cancer. , 2010, Cancer research.

[9]  Steven Eschrich,et al.  Prediction of radiation sensitivity using a gene expression classifier. , 2005, Cancer research.

[10]  D. de Ruysscher,et al.  Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  S. Bhattarai,et al.  Post-transcriptional regulation of MRE11 expression in muscle-invasive bladder tumours , 2014, Oncotarget.

[12]  Crispin J. Miller,et al.  A 26-Gene Hypoxia Signature Predicts Benefit from Hypoxia-Modifying Therapy in Laryngeal Cancer but Not Bladder Cancer , 2013, Clinical Cancer Research.

[13]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[14]  Joshua Jones,et al.  Role of radiation therapy in palliative care of the patient with cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Jeffrey W. Clark,et al.  Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. , 2011, The Lancet. Oncology.

[16]  L. Skoog,et al.  Intact Mre11/Rad50/Nbs1 complex predicts good response to radiotherapy in early breast cancer. , 2007, International journal of radiation oncology, biology, physics.

[17]  A. Kibel,et al.  Radiotherapy with or Without Chemotherapy in Muscle-Invasive Bladder Cancer , 2012 .

[18]  Martin Kühne,et al.  A pathway of double-strand break rejoining dependent upon ATM, Artemis, and proteins locating to gamma-H2AX foci. , 2004, Molecular cell.

[19]  G. Bussolati,et al.  Technical pitfalls potentially affecting diagnoses in immunohistochemistry , 2008, Journal of Clinical Pathology.

[20]  B. Freidlin,et al.  Statistical and practical considerations for clinical evaluation of predictive biomarkers. , 2013, Journal of the National Cancer Institute.

[21]  E. Rutgers,et al.  Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  J Wade Harper,et al.  The DNA damage response: ten years after. , 2007, Molecular cell.

[23]  David Boulware,et al.  A gene expression model of intrinsic tumor radiosensitivity: prediction of response and prognosis after chemoradiation. , 2009, International journal of radiation oncology, biology, physics.

[24]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[25]  Sung-Bae Kim,et al.  Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. , 2012, The New England journal of medicine.

[26]  A. Kiltie,et al.  Similar treatment outcomes for radical cystectomy and radical radiotherapy in invasive bladder cancer treated at a United Kingdom specialist treatment center. , 2008, International journal of radiation oncology, biology, physics.

[27]  F. Cappuzzo,et al.  First-line crizotinib versus chemotherapy in ALK-positive lung cancer. , 2014, The New England journal of medicine.

[28]  H. Bartelink,et al.  Gene expression profiling to predict the risk of locoregional recurrence in breast cancer: a pooled analysis , 2014, Breast Cancer Research and Treatment.

[29]  Hemant Ishwaran,et al.  An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer , 2008, Proceedings of the National Academy of Sciences.

[30]  N. McGranahan,et al.  The causes and consequences of genetic heterogeneity in cancer evolution , 2013, Nature.

[31]  Douglas G Altman,et al.  Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration , 2012, BMC Medicine.

[32]  W. Sauerbrei,et al.  Reporting recommendations for tumor marker prognostic studies (REMARK). , 2005, Journal of the National Cancer Institute.

[33]  F. Waldman,et al.  Reproducibility of p53 Immunohistochemistry in Bladder Tumors , 2000 .

[34]  Dorota H. Sendorek,et al.  NBN gain is predictive for adverse outcome following image-guided radiotherapy for localized prostate cancer , 2014, Oncotarget.

[35]  L. Påhlman,et al.  Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[36]  S. A. Roberts,et al.  The independence of intrinsic radiosensitivity as a prognostic factor for patient response to radiotherapy of carcinoma of the cervix. , 1997, British Journal of Cancer.

[37]  J. Baselga,et al.  Trastuzumab emtansine for HER2-positive advanced breast cancer. , 2012, The New England journal of medicine.

[38]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[39]  John M S Bartlett,et al.  Updated UK Recommendations for HER2 assessment in breast cancer , 2014, Journal of Clinical Pathology.

[40]  P. Span,et al.  Expression of the BRCA1 complex member BRE predicts disease free survival in breast cancer , 2012, Breast Cancer Research and Treatment.

[41]  P. Hoskin,et al.  Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  Hyun Cheol Chung,et al.  Identification of a radiosensitivity signature using integrative metaanalysis of published microarray data for NCI-60 cancer cells , 2011, BMC Genomics.

[43]  Ping Li,et al.  A radiosensitivity gene signature in predicting glioma prognostic via EMT pathway , 2014, Oncotarget.

[44]  Abhi Veerakumarasivam,et al.  Loss of expression of the tumour suppressor gene AIMP3 predicts survival following radiotherapy in muscle‐invasive bladder cancer , 2014, International journal of cancer.

[45]  C. Mathers,et al.  GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer , 2013 .

[46]  S. Toyooka,et al.  Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. , 2010, The Lancet. Oncology.

[47]  Geoff Delaney,et al.  The role of radiotherapy in cancer treatment , 2005, Cancer.

[48]  Van,et al.  A gene-expression signature as a predictor of survival in breast cancer. , 2002, The New England journal of medicine.

[49]  T. Shibata,et al.  Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  A. Frigessi,et al.  Development and Validation of a Gene Profile Predicting Benefit of Postmastectomy Radiotherapy in Patients with High-Risk Breast Cancer: A Study of Gene Expression in the DBCG82bc Cohort , 2014, Clinical Cancer Research.

[51]  J. Staffurth,et al.  A review of the clinical evidence for intensity-modulated radiotherapy. , 2010, Clinical oncology (Royal College of Radiologists (Great Britain)).

[52]  T. Eberlein.  A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer , 2006 .

[53]  T. Ørntoft,et al.  Next-generation sequencing identifies germline MRE11A variants as markers of radiotherapy outcomes in muscle-invasive bladder cancer , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.